WEBULL
WebtradeDownload

Stryker (SYK) Unveils New Ankle Tools, Is The 12% Undervaluation Real?

Simply Wall St · 23h ago

Stryker (SYK) drew fresh attention after unveiling new Foot & Ankle technologies at the 2026 AOFAS meeting, including Prophecy Surgical Planning for the Incompass Total Ankle System and Hoffmann LRF smartHEX for limb reconstruction.

Against that product backdrop, Stryker’s share price has retreated, with a 30 day share price return down about 19% and the year to date share price return down about 21%, while the 1 year total shareholder return is down about 26%. This points to fading momentum despite ongoing product launches and an acceleration story flagged for 2027.

Scan Stryker’s pullback against other medical technology players by reviewing the hand picked list of solid balance sheet and fundamentals (23 results).

Stryker’s slide has reset expectations, yet the product pipeline and current pricing point in different directions. Has most of the easy upside already played out, or is this where the value case really starts?

Most Popular Narrative: 11.6% Undervalued

The most followed narrative on Stryker pegs fair value at $311.21 per share, compared with the last close at $275.12. That gap frames the recent pullback as a valuation reset rather than a complete break in the long term story.

Stryker is my defensive growth anchor, a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.

See why 1 investors see Stryker as 12% undervalued.

Result: Fair Value of $311.21 (UNDERVALUED)

Still, Stryker’s premium valuation and reliance on hospital capital budgets could quickly pressure the narrative if procedure demand softens or if new projects face delays.

Find out about the key risks to this Stryker narrative.

Next Steps

Sentiment on Stryker is split right now, with clear risks on one side and meaningful positives on the other. Move quickly and test the data yourself against your own framework, then weigh up the 4 key rewards and 2 important warning signs.

Looking for more Stryker sized investment ideas?

You have already done the hard work by digging into Stryker, so back that effort by lining up a few more candidates your future self might thank you for.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.